CLINICAL TRIALS PROFILE FOR PERFOROMIST
✉ Email this page to a colleague
All Clinical Trials for PERFOROMIST
Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
---|---|---|---|---|---|---|
NCT00633776 ↗ | Perforomist Versus Foradil Evaluated by Inspiratory Capacity and High Resolution Computed Tomography (HRCT) | Withdrawn | Dey, L.P. | Phase 4 | 2008-03-01 | The purpose of this study is to compare the effects of nebulized formoterol fumarate (Perforomist) to dry-powder inhaler formoterol fumarate (Foradil). Perforomist is a solution that is made into very fine spray (using a nebulizer) that is then breathed in over 10-15 minutes. Foradil is taken in a single quick, deep inhalation. |
NCT00633776 ↗ | Perforomist Versus Foradil Evaluated by Inspiratory Capacity and High Resolution Computed Tomography (HRCT) | Withdrawn | University of California, Los Angeles | Phase 4 | 2008-03-01 | The purpose of this study is to compare the effects of nebulized formoterol fumarate (Perforomist) to dry-powder inhaler formoterol fumarate (Foradil). Perforomist is a solution that is made into very fine spray (using a nebulizer) that is then breathed in over 10-15 minutes. Foradil is taken in a single quick, deep inhalation. |
NCT01488019 ↗ | Study to Evaluate the Safety of Long-Term Use of Perforomist® (Formoterol Fumarate) | Completed | Dey | Phase 4 | 2012-03-01 | This study is a multi-center, randomized, placebo-controlled study to evaluate the long-term safety of Perforomist® inhalation therapy in subjects with Chronic Obstructive Pulmonary Disease (COPD). Individual participation is approximately 54 weeks, including 52 weeks of double-blind treatment. |
>Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for PERFOROMIST
Condition Name
Clinical Trial Locations for PERFOROMIST
Trials by Country
Clinical Trial Progress for PERFOROMIST
Clinical Trial Phase
Clinical Trial Sponsors for PERFOROMIST
Sponsor Name